skip to main content

ALK-positive metastatic NSCLC — SCE Respiratory MCQ

Instant feedback + full explanation. One question, done properly.

HardLung CancerALK-positive metastatic NSCLCSCE Respiratory

A 54-year-old never-smoker has metastatic ALK-rearranged lung adenocarcinoma with liver metastases. Performance status is 1 and brain MRI is negative. What is the most appropriate management?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: C — Start first-line ALK inhibitor therapy

ALK-rearranged metastatic NSCLC should be treated with an ALK inhibitor as first-line targeted therapy when available. Chemotherapy may be used later or when targeted treatment is unsuitable, but molecularly matched therapy is preferred initially. Curative lobectomy is not appropriate in metastatic disease.

Reference: NICE NG122 Lung Cancer; NICE Technology Appraisals for ALK-positive NSCLC